Table 1.

Estimations used to model the burden of HCV in Turkey

a. Base 2017 scenario
	2015	2016	2017 & 2018	2018	2019	≥2020
Treated	4200	5600	10,200	9500	8800	5600
Newly diagnosed	5500	5500	5500	5500	5500	5500
Fibrosis stage	≥F0	≥F3	≥F1	≥F1	≥F1	≥F1
Treated age	15–79	15–79	15–79	15–79	15–79	15–79
SVR	49%	97%	99%	99%	99%	99%
b. Increased treatment scenario
	2015	2016	2017 & 2018	2019	2020–2024	≥2025
Treated	4200	5600	10,200	11,000	11,000	11,000
Newly diagnosed	5500	5500	5500	5500	5500	5500
Fibrosis stage	≥F0	≥F3	≥F1	≥F0	≥F0	≥F0
Treated age	15–79	15–79	15–79	15–79	15–79	15–79
SVR	49%	97%	99%	99%	99%	99%
c. WHO targets scenario
	2015	2016	2017 & 2018	2019	2021–2024	≥2025
Treated	4200	5600	10,200	15,000	16,000	16,000
Newly diagnosed	5500	5500	5500	6000	18,000	18,000
Fibrosis stage	≥F0	≥F3	≥F1	≥F1	≥F0	≥F0
Treated age	15–79	15–79	15–79	15–79	15–79	15–79
SVR	49%	97%	99%	99%	99%	99%